WHERE ARE YOU?

Concept Pre-Sub Submission prep Newly cleared Raising Exit Postmarket & security

THE TAPE

FDA panel backs GRAIL's Galleri on a 6 to 4 effectiveness vote TriSalus clears TriNav Advance, its fourth pressure-enabled infusion device Anaconda Biomed raises $56M to finish a 327-patient stroke trial FDA issues an early alert on Impella controllers that miss purge cassettes HighLife raises 80 million euros for a mitral valve CE marked in January Xenix Medical clears the Riva Anchor for sacroiliac fusion at the base of a lumbar construct Dialybrid raises 15 million euros as its silk polyurethane dialysis graft reaches a first patient CMS posts preliminary 2027 lab rates and cuts more than 1,100 test codes FDA approves Cordis Selution SLR, the first sirolimus drug-eluting balloon sold in the US FDA panel backs GRAIL's Galleri on a 6 to 4 effectiveness vote TriSalus clears TriNav Advance, its fourth pressure-enabled infusion device Anaconda Biomed raises $56M to finish a 327-patient stroke trial FDA issues an early alert on Impella controllers that miss purge cassettes HighLife raises 80 million euros for a mitral valve CE marked in January Xenix Medical clears the Riva Anchor for sacroiliac fusion at the base of a lumbar construct Dialybrid raises 15 million euros as its silk polyurethane dialysis graft reaches a first patient CMS posts preliminary 2027 lab rates and cuts more than 1,100 test codes FDA approves Cordis Selution SLR, the first sirolimus drug-eluting balloon sold in the US

Equity round

Anaconda Biomed raises $56M to finish a 327-patient stroke trial

MedDevice Startups Staff · 1 day ago · 2 min read · Via Anaconda Biomed

Anaconda Biomed closed a $56M equity round on September 23. Omega Funds led. The Co-investment Fund FOCO, managed by COFIDES, joined alongside Asabys through Sabadell Asabys II, Ysios Capital and CDTI through its SICC Innvierte vehicle.

Most of the money goes to ATHENA, a prospective randomized IDE study enrolling 327 subjects. The trial tests the ANA Funnel Catheter, used with a stent retriever during thrombectomy for large vessel occlusion acute ischemic stroke. The catheter is investigational in the US. The ANA5 funnel catheter carries a CE mark.

The company operates from Marin, California with its engineering base in Barcelona, and is also working on the ANA6, ANA8 and a stent retriever called Conda. Raising to finish a randomized IDE trial rather than to launch a cleared product is a choice about the label, and it costs years.

Questions & Answers

How much did Anaconda Biomed raise in September 2026 and who led the round?

Anaconda Biomed announced a $56M equity financing on September 23, 2026. Omega Funds led, with COFIDES through its Co-investment Fund FOCO, Asabys through Sabadell Asabys II, Ysios Capital and CDTI through SICC Innvierte participating.

What is the Anaconda Biomed ANA Funnel Catheter used for?

The ANA Funnel Catheter is used alongside a stent retriever during thrombectomy to remove clots in patients with large vessel occlusion acute ischemic stroke. It is investigational in the United States.

What is the ATHENA trial for Anaconda Biomed?

ATHENA is a prospective randomized IDE study enrolling 327 subjects to evaluate the safety and performance of Anaconda Biomed's ANA Funnel Catheter. Most of the September 2026 $56M round funds its completion.

← Back to Fundraising